|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities: | |||||
| Net earnings (loss) | |||||
| Adjustments to reconcile net income (loss) to cash used in operating activities: | |||||
| Depreciation expense | |||||
| Stock-based compensation expense | |||||
| Non-cash gain on change in fair value of warrant liability | |||||
| Amortization of discounts on marketable investment securities | |||||
| Write off of contract asset due to variable consideration revenue reversal | |||||
| Changes in operating assets and liabilities: | |||||
| Accrued interest income | |||||
| Contract asset | |||||
| License and royalties receivable | |||||
| Prepaid and other current assets | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Deferred revenue | |||||
| Cash used in operating activities | |||||
| Cash flows from investing activities: | |||||
| Purchase of property and equipment | |||||
| Purchases of marketable investment securities | |||||
| Maturities of marketable investment securities | |||||
| Cash provided by investing activities | |||||
| Cash flows from financing activities: | |||||
| Net proceeds of common stock sold | |||||
| Cash provided by financing activities | |||||
| Net increase (decrease) in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of period | |||||
| Cash and cash equivalents at end of period | |||||
| Supplemental disclosure of cash flow information: | |||||
| Income taxes paid | |||||
| Supplemental disclosure of non-cash investing and financing activity: | |||||
| Net unrealized gain (loss) on available-for-sale securities | |||||
| Issuance of Series B preferred stock | |||||
Loading...